| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1037231999 |
| P356 | DOI | 10.1038/BJC.2013.451 |
| P932 | PMC publication ID | 3778302 |
| P698 | PubMed publication ID | 23922104 |
| P5875 | ResearchGate publication ID | 255695229 |
| P2093 | author name string | H Gelderblom | |
| B Herpers | |||
| B van de Water | |||
| I H Briaire-de Bruijn | |||
| J G van Oosterwijk | |||
| J V M G Bovée | |||
| M A J H van Ruler | |||
| P2860 | cites work | Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway | Q24537174 |
| The role of Src in solid tumors | Q24616659 | ||
| A transforming mutation in the pleckstrin homology domain of AKT1 in cancer | Q27646556 | ||
| PI3K-independent AKT activation in cancers: a treasure trove for novel therapeutics | Q28259003 | ||
| Fyn: a novel molecular target in cancer | Q28273098 | ||
| Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. | Q45198729 | ||
| The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts | Q46652649 | ||
| p53 mutations in chondrosarcoma | Q47912947 | ||
| Marshall Urist Award. Interstitial collagenase gene expression correlates with in vitro invasion in human chondrosarcoma. | Q48373123 | ||
| Establishment and characterization of a continuous human chondrosarcoma cell line, ch-2879: comparative histologic and genetic studies with its tumor of origin. | Q52828622 | ||
| Absence of IHH and retention of PTHrP signalling in enchondromas and central chondrosarcomas. | Q53361172 | ||
| Dedifferentiated central chondrosarcoma. | Q53538423 | ||
| Dasatinib sensitizes primary chronic lymphocytic leukaemia lymphocytes to chlorambucil and fludarabinein vitro | Q58436764 | ||
| Prognostic factors in chondrosarcoma of bone: a clinicopathologic analysis with emphasis on histologic grading | Q67652553 | ||
| An in vitro assay procedure to test chemotherapeutic drugs on cells from human solid tumors | Q71393762 | ||
| Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma | Q73351349 | ||
| Altered p53 is associated with aggressive behavior of chondrosarcoma: a long term follow-up study | Q77639213 | ||
| The use of Bcl-2 and PTHLH immunohistochemistry in the diagnosis of peripheral chondrosarcoma in a clinicopathological setting | Q81471590 | ||
| Restoration of chemosensitivity for doxorubicin and cisplatin in chondrosarcoma in vitro: BCL-2 family members cause chemoresistance | Q82659226 | ||
| High-throughput live cell imaging of apoptosis | Q84348390 | ||
| Expression of ezrin, Bcl-2, and Ki-67 in chondrosarcomas | Q85054749 | ||
| FYN is overexpressed in human prostate cancer | Q28300097 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| Tissue microarrays for high-throughput molecular profiling of tumor specimens | Q29618675 | ||
| PKC-eta mediates glioblastoma cell proliferation through the Akt and mTOR signaling pathways | Q30434836 | ||
| Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor | Q33276227 | ||
| GSK-3beta promotes cell survival by modulating Bif-1-dependent autophagy and cell death | Q33701939 | ||
| Prolactin enhances insulin-like growth factor I receptor phosphorylation by decreasing its association with the tyrosine phosphatase SHP-2 in MCF-7 breast cancer cells | Q33707003 | ||
| First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia | Q33843477 | ||
| The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro | Q33860510 | ||
| Small-molecule inhibitors of the PI3K signaling network | Q33883982 | ||
| Activation of Src kinase in primary colorectal carcinoma: an indicator of poor clinical prognosis | Q34119101 | ||
| Mechanisms by which IGF-I may promote cancer | Q34180961 | ||
| IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not in other mesenchymal tumours | Q34186353 | ||
| Three new chondrosarcoma cell lines: one grade III conventional central chondrosarcoma and two dedifferentiated chondrosarcomas of bone | Q34396287 | ||
| c-Src protein expression is increased in human breast cancer. An immunohistochemical and biochemical analysis | Q34414942 | ||
| The clinical approach towards chondrosarcoma | Q34766148 | ||
| MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function | Q35965859 | ||
| Global tumor protein p53/p63 interactome: making a case for cisplatin chemoresistance. | Q36059712 | ||
| Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome | Q36190010 | ||
| Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy | Q36736714 | ||
| The role of Src in prostate cancer | Q36787631 | ||
| Establishment of novel human dedifferentiated chondrosarcoma cell line with osteoblastic differentiation | Q36892224 | ||
| Dasatinib combined with docetaxel for castration-resistant prostate cancer: results from a phase 1-2 study | Q37502039 | ||
| Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. | Q37763842 | ||
| Src-family tyrosine kinases as therapeutic targets in advanced cancer | Q37881543 | ||
| Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. | Q37888979 | ||
| IGF-I enhances α5β1 integrin expression and cell motility in human chondrosarcoma cells | Q39587526 | ||
| Dasatinib plus Nutlin-3 shows synergistic antileukemic activity in both p53 wild-type and p53 mutated B chronic lymphocytic leukemias by inhibiting the Akt pathway | Q39627892 | ||
| Anti-leukemic activity of dasatinib in both p53(wild-type) and p53(mutated) B malignant cells | Q39643077 | ||
| Roles of Fyn in pancreatic cancer metastasis | Q39766021 | ||
| Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. | Q39825289 | ||
| Estrogen signaling is active in cartilaginous tumors: implications for antiestrogen therapy as treatment option of metastasized or irresectable chondrosarcoma | Q40349229 | ||
| Activation of BAD by therapeutic inhibition of epidermal growth factor receptor and transactivation by insulin-like growth factor receptor | Q40732059 | ||
| The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors | Q40775807 | ||
| Regulation of both apoptosis and cell survival by the v-Src oncoprotein. | Q40864831 | ||
| A new human chondrosarcoma cell line (OUMS-27) that maintains chondrocytic differentiation | Q41013051 | ||
| Differential regulation of glycogen synthase kinase-3 beta by protein kinase C isotypes | Q41607785 | ||
| Curcumin modulates microRNA-203-mediated regulation of the Src-Akt axis in bladder cancer | Q41992399 | ||
| The Bone Niche of Chondrosarcoma: A Sanctuary for Drug Resistance, Tumour Growth and also a Source of New Therapeutic Targets. | Q42084526 | ||
| Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCβ | Q44442888 | ||
| Protein kinase C betaII regulates Akt phosphorylation on Ser-473 in a cell type- and stimulus-specific fashion. | Q45057108 | ||
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | doxorubicin | Q18936 |
| cell migration | Q189092 | ||
| dasatinib | Q419940 | ||
| chondrosarcoma | Q1076087 | ||
| dasatinib monohydrate | Q27139135 | ||
| P304 | page(s) | 1214-1222 | |
| P577 | publication date | 2013-08-06 | |
| P1433 | published in | British Journal of Cancer | Q326309 |
| P1476 | title | Src kinases in chondrosarcoma chemoresistance and migration: dasatinib sensitises to doxorubicin in TP53 mutant cells | |
| P478 | volume | 109 |
| Q91938750 | A screening-based approach identifies cell cycle regulators AURKA, CHK1 and PLK1 as targetable regulators of chondrosarcoma cell survival |
| Q100464168 | A system-level approach identifies HIF-2α as a critical regulator of chondrosarcoma progression |
| Q46128938 | Advances in the pathogenesis and possible treatments for multiple hereditary exostoses from the 2016 international MHE conference |
| Q38946440 | An orthotopic mouse model for chondrosarcoma of bone provides an in vivo tool for drug testing |
| Q53083279 | Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype. |
| Q38884578 | Application of xCELLigence RTCA Biosensor Technology for Revealing the Profile and Window of Drug Responsiveness in Real Time. |
| Q38904172 | Basic fibroblast growth factor induces VEGF expression in chondrosarcoma cells and subsequently promotes endothelial progenitor cell-primed angiogenesis. |
| Q58705635 | Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma |
| Q48182725 | Chondrosarcoma: A Rare Misfortune in Aging Human Cartilage? The Role of Stem and Progenitor Cells in Proliferation, Malignant Degeneration and Therapeutic Resistance. |
| Q50643010 | Doxorubicin delivered by a redox-responsive dasatinib-containing polymeric prodrug carrier for combination therapy. |
| Q53070824 | Genetic alterations in chondrosarcomas - keys to targeted therapies? |
| Q91276909 | Gjb4 serves as a novel biomarker for lung cancer and promotes metastasis and chemoresistance via Src activation |
| Q59341006 | Kinome-Wide siRNA Screening Identifies Src-Enhanced Resistance of Chemotherapeutic Drugs in Triple-Negative Breast Cancer Cells |
| Q36078319 | No preclinical rationale for IGF1R directed therapy in chondrosarcoma of bone |
| Q38764510 | Novel therapeutic approaches in chondrosarcoma. |
| Q33276227 | Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epithelioid sarcoma, or solitary fibrous tumor |
| Q49158742 | Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a TransPORTEC initiative |
| Q27727987 | Structural and Biochemical Basis for Intracellular Kinase Inhibition by Src-specific Peptidic Macrocycles |
| Q88167587 | Targeting glutaminolysis in chondrosarcoma in context of the IDH1/2 mutation |
| Q36527950 | Targeting protein kinases to reverse multidrug resistance in sarcoma. |
| Q42419178 | Targeting survivin as a potential new treatment for chondrosarcoma of bone |
| Q35802929 | The importance of Src signaling in sarcoma |
| Q38175044 | The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development |
| Q38984111 | Using real-time impedance-based assays to monitor the effects of fibroblast-derived media on the adhesion, proliferation, migration and invasion of colon cancer cells. |
Search more.